Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Research & Development (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Research & Development for 11 consecutive years, with $45.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 1.12% year-over-year to $45.2 million, compared with a TTM value of $177.5 million through Sep 2025, up 21.58%, and an annual FY2024 reading of $162.8 million, up 81.88% over the prior year.
  • Research & Development was $45.2 million for Q3 2025 at Spyre Therapeutics, up from $40.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $50.5 million in Q4 2024 and bottomed at $11.9 million in Q1 2021.
  • Average Research & Development over 5 years is $26.1 million, with a median of $17.4 million recorded in 2023.
  • The sharpest move saw Research & Development decreased 19.5% in 2021, then soared 153.54% in 2024.
  • Year by year, Research & Development stood at $16.8 million in 2021, then decreased by 15.08% to $14.3 million in 2022, then surged by 136.35% to $33.7 million in 2023, then surged by 49.88% to $50.5 million in 2024, then fell by 10.37% to $45.2 million in 2025.
  • Business Quant data shows Research & Development for SYRE at $45.2 million in Q3 2025, $40.1 million in Q2 2025, and $41.6 million in Q1 2025.